News

Can Genetic Testing Identify the Best Treatment for Metastatic, Castration-Resistant Prostate Cancer?

Patients with metastatic, castration-resistant prostate cancer (mCRPC) have a median overall survival of only about two to three years, but genomic sequencing is making inroads against that grim prognosis.

Video

Meet the Team: Ankit Patel, MD

The newest member of Roswell Park Comprehensive Cancer Center’s melanoma and sarcoma team considers his appointment a homecoming.

Video

Cellular Therapies Leading to New Treatment Options for Lymphoma Patients

A new CAR T-cell consortium, Matthew Cortese, MD, MPH, a hematologic oncologist at Roswell Park Comprehensive Cancer Center, shares that certain types of hard-to-treat lymphomas may be more receptive to immunotherapies than previously thought.

Document

Is Subcutaneous Immunotherapy Ready for Prime Time? Join the June 23 webinar

Physicians are invited to join a panel of experts from Roswell Park Comprehensive Cancer Center on Tuesday, June 23 for a discussion on the use of subcutaneous immunotherapy.

Document

Join Roswell Park Expert at 2nd Annual Upstate Cancer Symposium June 21

The Oncology Brothers, including Roswell Park Comprehensive Cancer Center’s Rohit Gosain, MD, are hosting the second annual Upstate Cancer Symposium in Buffalo on June 21.

Video

New Immunotherapy Trials Offer Hope to Previously Excluded Gynecologic Cancer Patients

Roswell Park Comprehensive Cancer Center offers gynecologic cancer patients multidisciplinary care from nationally recognized specialists who collaborate on personalized treatment plans.